Korean J Urol.  2010 Apr;51(4):239-244.

Correlation between Claudins Expression and Prognostic Factors in Prostate Cancer

• Seo KW
• Kwon YK
• Kim BH
• Kim CI
• Chang HS
• Choe MS
• Park CH

Abstract

PURPOSE
The purpose of this study was to evaluate the correlation between the expression of claudins and prognostic factors in patients with prostate cancer. MATERIALS AND METHODS: The subjects of this study were 48 patients who had undergone surgery for prostate cancer. The Gleason score (6 or lower, 7 or higher), prostate-specific antigen (PSA) level, T stage, biochemical recurrence, local recurrence, and distant metastasis were compared according to the expression of claudin-1 and claudin-5 in prostate cancer. RESULTS: In the group with a low expression of claudin-1, the Gleason score was 7 points or higher in 18 cases (82%) and 6 points or lower in 4 cases (18%). In the group with a high expression of claudin-1, the Gleason score was 7 points or higher in 13 cases (50%) and 6 points or lower in 13 cases (50%). Thus, the low-expression group had more cases with a Gleason score of 7 or higher (p=0.022). The group with a low expression of claudin-5 also had more cases with a Gleason score of 7 or higher (p=0.011). The mean PSA values in the groups with a low and high expression of claudin-1 were 9.6 ng/ml and 5.6 ng/ml, respectively (p=0.007). A low expression of claudin-5 was also associated with a high PSA value (p=0.002). There was no statistical difference in the expression of claudin-1 and claudin-5 by T stage, biochemical recurrence, local recurrence, or distant metastasis. CONCLUSIONS: The low expression of claudin-1, claudin-5 was associated with a Gleason score of 7 or higher and a high PSA value in prostate cancer.

Keyword

Claudin 1; CLDN5 protein; Prostate-specific antigen; Prostatic neoplasms

MeSH Terms

Claudin-1
Claudin-5
Claudins
Humans
Neoplasm Grading
Neoplasm Metastasis
Prostate
Prostate-Specific Antigen
Prostatic Neoplasms
Recurrence
Claudin-1
Claudin-5
Claudins
Prostate-Specific Antigen

Figure

• 

  FIG. 1 Claudin-1 expression in prostate malignancy tissues (anti-claudin-1 antibody, ×400). (A) Loss of membranous claudin-1 expression in a case of high-grade PCa. (B) High expression of membranous claudin-1 protein in a case of low-grade PCa. PCa: prostate cancer.

• 

  FIG. 2 Claudin-5 expression in prostate malignancy tissues (anti-claudin-5 antibody, ×400). (A) Loss of membranous claudin-5 expression in a case of high-grade PCa. (B) High expression of membranous claudin-5 protein in a case of low-grade PCa. PCa: prostate cancer.

Reference

1. Oliver SE, May MT, Gunnell D. International trends in prostate-cancer mortality in the "PSA ERA". Int J Cancer. 2001; 92:893–898. PMID: 11351313.

2. Väre P, Loikkanen I, Hirvikoski P, Vaarala MH, Soini Y. Low claudin expression is associated with high Gleason grade in prostate adenocarcinoma. Oncol Rep. 2008; 19:25–31. PMID: 18097572.

3. Furuse M, Fujita K, Hiiragi T, Fujimoto K, Tsukita S. Claudin-1 and -2: novel integral membrane proteins localizing at tight junctions with no sequence similarity to occludin. J Cell Biol. 1998; 141:1539–1550. PMID: 9647647.

4. Tsukita S, Furuse M. Claudin-based barrier in simple and stratified cellular sheets. Curr Opin Cell Biol. 2002; 14:531–536. PMID: 12231346.

5. Sawada N, Murata M, Kikuchi K, Osanai M, Tobioka H, Kojima T, et al. Tight junctions and human diseases. Med Electron Microsc. 2003; 36:147–156. PMID: 14505058.

6. Matsuda M, Kubo A, Furuse M, Tsukita S. A peculiar internalization of claudins, tight junction-specific adhesion molecules, during the intercellular movement of epithelial cells. J Cell Sci. 2004; 117:1247–1257. PMID: 14996944.

7. Jiang WG, Puntis MC, Hallett MB. Molecular and cellular basis of cancer invasion and metastasis: implications for treatment. Br J Surg. 1994; 81:1576–1590. PMID: 7827878.

8. Turksen K, Troy TC. Barriers built on claudins. J Cell Sci. 2004; 117:2435–2447. PMID: 15159449.

9. Miwa N, Furuse M, Tsukita S, Niikawa N, Nakamura Y, Furukawa Y. Involvement of claudin-1 in the bata-catenin/Tcf signaling pathway and its frequent upregulation in human colorectal cancers. Oncol Res. 2001; 12:469–476. PMID: 11939410.

10. Tsukahara M, Nagai H, Kamiakito T, Kawata H, Takayashiki N, Saito K, et al. Distinct expression patterns of claudin-1 and claudin-4 in intraductal papillary-mucinous tumors of the pancreas. Pathol Int. 2005; 55:63–69. PMID: 15693851.

11. Kominsky SL, Argani P, Korz D, Evron E, Raman V, Garrett E, et al. Loss of the tight junction protein claudin-7 correlates with histological grade in both ductal carcinoma in situ and invasive ductal carcinoma of the breast. Oncogene. 2003; 22:2021–2033. PMID: 12673207.

12. Tokes AM, Kulka J, Paku S, Szik A, Páska C, Novák PK, et al. Claudin-1, -3 and -4 proteins and mRNA expression in benign and malignant breast lesions: a research study. Breast Cancer Res. 2005; 7:R296–R305. PMID: 15743508.

13. Hough CD, Sherman-Baust CA, Pizer ES, Montz FJ, Im DD, Rosenshein NB, et al. Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer. Cancer Res. 2000; 60:6281–6287. PMID: 11103784.

14. Long H, Crean CD, Lee WH, Cummings OW, Gabig TG. Expression of Clostridium perfringens enterotoxin receptors claudin-3 and claudin-4 in prostate cancer epithelium. Cancer Res. 2001; 61:7878–7881. PMID: 11691807.

15. Gumbiner BM. Cell adhesion: the molecular basis of tissue architecture and morphogenesis. Cell. 1996; 84:345–357. PMID: 8608588.

16. Gonzalez-Mariscal L, Betanzos A, Nava P, Jaramillo BE. Tight junction proteins. Prog Biophys Mol Biol. 2003; 81:1–44. PMID: 12475568.

17. Hornsby CD, Cohen C, Amin MB, Picken MM, Lawson D, Yin-Goen Q, et al. Claudin-7 immunohistochemistry in renal tumors: a candidate marker for chromophobe renal cell carcinoma identified by gene expression profiling. Arch Pathol Lab Med. 2007; 131:1541–1546. PMID: 17922590.

18. Nichols LS, Ashfaq R, Iacobuzio-Donahue CA. Claudin 4 protein expression in primary and metastatic pancreatic cancer: support for use as a therapeutic target. Am J Clin Pathol. 2004; 121:226–230. PMID: 14983936.

19. Lee SM, Lee JH, Kim BG, Kim YS, Park YG, Chi KC, et al. Correlation of decreased expressions of claudin 4 and E-cadherin proteins and the clinicopathologic factors of stomach cancer. J Korean Surg Soc. 2007; 73:221–226.

20. Tokés AM, Kulka J, Paku S, Máthé M, Páska C, Lódi C, et al. The expression of five different claudins in invasive breast carcinomas: comparison of pT1pN1 and pT1pN0 tumors. Pathol Res Pract. 2005; 201:537–544. PMID: 16259105.

21. Soler AP, Miller RD, Laughlin KV, Carp NZ, Klurfeld DM, Mullin JM. Increased tight junctional permeability is associated with the development of colon cancer. Carcinogenesis. 1999; 20:1425–1431. PMID: 10426787.

22. Choi HJ, Jung JH, Yoo J, Kang SJ, Lee KY. Expression of claudin-1 and -4 in benign lesions and invasive ductal carcinomas of the breast. Korean J Pathol. 2007; 41:232–237.

23. Sheehan GM, Kallakury BV, Sheehan CE, Fisher HA, Kaufman RP Jr, Ross JS. Loss of claudins-1 and -7 and expression of claudins-3 and -4 correlate with prognostic variables in prostatic adenocarcinomas. Hum Pathol. 2007; 38:564–569. PMID: 17306334.

24. Landers KA, Samaratunga H, Teng L, Buck M, Burger MJ, Scells B, et al. Identification of claudin-4 as a marker highly overexpressed in both primary and metastatic prostate cancer. Br J Cancer. 2008; 99:491–501. PMID: 18648369.

25. Zheng JY, Yu D, Foroohar M, Ko E, Chan J, Kim N, et al. Regulation of the expression of the prostate-specific antigen by claudin-7. J Membr Biol. 2003; 194:187–197. PMID: 14502431.